Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford and benefits from excellent links with the global Ludwig and local Oxford research communities.
Listen to Ludwig scientist Skirmantas Kriaucionis discussing his research on epigenetics and cancer. Epigenetic modifications such as methylations alter which sets of genes are expressed in specific cells and how this specificity is inherited across cell divisions. Cancer cells show particular epigenetic abnormalities which can be targeted for cancer therapies. More podcasts are available here
Cancer Genetics May Aid Diagnostics of Developmental Disorders. Hum Mutat, 37 (10), pp. 989. Article
Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genet, 12 (9), pp. e1006279. Article
SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Mol Cell, 63 (6), pp. 990-1005. Article
Parallel reverse genetic screening in mutant human cells using transcriptomics. Mol Syst Biol, 12 (8), pp. 879. Article
ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome. Cell Death Differ. Article
Our researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Many of the research groups are interested the causes and consequences of differences among cells within a tumour and variability among different tumours. Find out more about the Ludwig research groups.
Ludwig Seminars take place in the NDMRB (TDI) Basement Seminar Room. All University members welcome.
Juliane Liepe, Michele Mishto: From in silico to the clinic: methods to study proteasome catalysed peptide splicing - AND - Proteasome-Catalyzed peptide splicing and its immunological relevance, 07/Dec/2016 10:00
Browse the Ludwig Seminar Series